If 2024 looks like 1901, maybe you are doing it wrong.

All physicians should keep these images in mind next time you’re stuck with 87 clicks to release a MAR or input an ICD-10 code. When you can’t find a simple lab result or note… When you can’t access results from a hospital down the street… When your inbox and Epic chat is

1/Excited to share our latest research led by Chester Kao & Soren Charmsaz , published in Journal of Clinical Investigation! ➡️We found that immune-related adverse events (irAEs) in patients receiving IO are linked to Th17 and Th2 signatures jci.org/articles/view/…

Congrats Steph for this well-deserved recognition and for leading this important project! American College of Rheumatology #ACR24 Abstract: acrabstracts.org/abstract/trbv9…

Congrats to Jin Liu for being awarded the ACR Emerging Investigator Excellence Award for her work on 9G4-targeted CAR/cTCR-T cells for the treatment of lupus. #ACR24 Johns Hopkins Rheumatology #ProundMentorMoment

Congrats to Steph Glavaris for being awarded the ACR Emerging Investigator Excellence Award for her work on T cell-engaging antibodies to deeply deplete TRBV9+, autoreactive T cells in ankylosing spondylitis and celiac disease. #ACR24 Johns Hopkins Rheumatology Chris Marston #ProundMentorMoment

While at it, if you are interested in learning more about off-the-shelf precision immunotherapies for the treatment of lupus, please join our talk on 9G4xCD3 T cell-engaging antibodies during the SLE - Cellular Therapy Session at 3 PM. #ACR24 Johns Hopkins Medicine Johns Hopkins Rheumatology

Targeting autoreactive T cells using TRBV9xCD3 bispecific T cell engaging antibodies. Controlling ankylosing spondylitis and celiac disease without increasing the risk of infection? Let's go. Join us in Room 150, at 3:00 PM. #precisionimmunotherapy #ACR24

Grateful for the incredible experience at #ACR2024! Honored to present my work! A huge thank you to my mentor, Max Konig for all your guidance and support, and to organizer American College of Rheumatology for this amazing opportunity and recognition! Shout out to our collaborators@jhrheumatology

Jan '25 #Advances in #Immunoengineering #Workshop! FREE Registration jhtie.jhmi.edu/training-upcom… Exciting speakers include: GarciaLabGT Mike Mitchell Kara L Spiller Max Konig @May_Daher W. Gregory Sawyer & More! NIBIB Johns Hopkins Medicine Johns Hopkins Engineering The Johns Hopkins Institute for NanoBioTechnology Johns Hopkins BME

VIRTUAL-LIVE-FREE - featuring keynote by Georg Schett!! & Max Konig Emily Littlejohn - join from anywhere & get our CAR-T newsletter for the yr! - REGISTER NOW Rheumatology Nurses RhAPP Association of Women in Rheumatology CreakyJoints.org Kimberly Prather, Ph.D. David Liew @DrPujaMehta1 Mike Putman clevelandclinicmeded.com/live/courses/c…

It's back! This year, #RheumMadness is releasing intro pods & "scouting reports" serially before March. Naturally starts with this great piece on CAR-T and BITEs which promise to revolutionize rheumatology care. Highly recommended for rheums & trainees 👇 pca.st/episode/fd6180…

Let's see if the T cell therapies collide this year. Madness.

I hope American voters realize how insane and dangerous it is for Trump to threaten another NATO ally to give up territory. Suppressing science, preventing communication about a looming pandemic, trying to overwrite constitutional rights. This is doing irreparable harm to the US.

The brain worms are now in charge of science and medicine in the United States. Forget curing cancer, we will bring back iron lungs and infant paralysis, suffocating children with diphtheria, and the snake oils against fully preventable diseases.

What are the implications for CAR-T cell therapy for autoimmune diseases? 1- we need safety switches 2- we need targeted editing approaches, not just random integration 3- we need to favor therapies that are rejected (e.g., most allogenic CAR-T cells get rejected) All exist.

Destroying leading scientific institutions one step at a time so we can funnel more billions to SpaceX?

Science cannot thrive without the next generation.